On Friday, Shares of Lions Gate Entertainment Corp. (USA) (NYSE:LGF), gained 0.80% to $ 39.30.
Lionsgate, and Hasbro, are teaming up to prove that “friendship is magic” as the two companies bring Hasbro’s world famous MY LITTLE PONY franchise to the big screen. Meghan McCarthy , fan-favorite writer and producer for the My Little Pony: Friendship is Magic animated series, is penning the screenplay, which will be produced by Hasbro’s Allspark Pictures. Lionsgate will be distributing and marketing the film globally (except in China ). Tony and Emmy Award-winning actress Kristin Chenoweth will voice a new character in the film, which is Hasbro’s first animated feature.
The MY LITTLE PONY brand has been enchanting fans of all ages worldwide for more than 30 years with its socially relevant messages of acceptance and friendship. What started in 1983 as a toy line of colorful ponies with unique symbols, called “cutie marks,” has since exploded into international, multi-media, pop culture phenomena that grossed over $1 billion in retail sales in 2014. The entertainment continues to engage and inspire kids and families in over 180 countries across the globe.
In the movie, a new dark force threatens Ponyville, and the Mane 6 – Twilight Sparkle, Applejack, Rainbow Dash, Pinkie Pie, Fluttershy and Rarity – embark on an unforgettable journey beyond Equestria where they meet new friends and exciting challenges on a quest to use the magic of friendship and save their home. The MY LITTLE PONY film will feature all new music with the Mane Six characters voiced by Tara Strong , Cathy Weseluck , Andrea Libman , Tabitha St. Germain and Ashleigh Ball . Jayson Theissen is directing. Brian Goldner and Stephen Davis are producing the film with Meghan McCarthy and Michael Vogel co-executive producing.
Lions Gate Entertainment Corp. engages in motion picture production and distribution, television programming and syndication, home entertainment, family entertainment, digital distribution, channel platforms, and international distribution and sales activities. The company operates through two segments, Motion Pictures and Television Production.
Shares of Mallinckrodt PLC (NYSE:MNK), inclined 0.50% to $98.52, during its last trading session.
Mallinckrodt plc, and The Gores Group, declared that they have reached a definitive agreement under which a partner of Mallinckrodt will acquire Therakos, Inc. a leading immunotherapy company in a transaction valued at about $1.325 billion. Subject to customary closing conditions, the parties expect the transaction to be accomplished in the latter part of the third calendar quarter of 2015, Mallinckrodt’s fourth fiscal quarter.
Therakos, Inc. is the global leader in autologous immune cell therapy delivered through extracorporeal photopheresis (ECP), and is focused on providing innovative treatment platforms that harness the power of patients’ immune systems to fight disease. Therakos Photopheresis is approved by the U.S. Food and Drug Administration for the palliative treatment of the skin manifestations of cutaneous T-cell lymphoma (CTCL) in persons who have not been responsive to other forms of treatment. Outside the U.S., Therakos Photopheresis is also broadly approved for ECP, and used by physicians in countries around the world in immune-modulating applications in a variety of conditions counting CTCL, Graft As compared to Host Disease, Crohn’s disease, solid organ transplants and other diseases.
Therakos therapeutic platforms, counting the latest generation Therakos CELLEXPhotopheresis System, are the world’s only approved, fully integrated systems for administering autologous immune cell therapy through ECP. Used by academic medical centers, hospitals and treatment centers in more than 25 countries, Therakos systems have been used to deliver over one million photopheresis treatments globally.
Mallinckrodt Public Limited Company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging.
At the end of Friday’s trade, Shares of Biodel Inc (NASDAQ:BIOD), lost -22.99% to $0.732.
Biodel Inc., stated financial results for the third fiscal quarter ended June 30, 2015.
Portfolio update since last fiscal quarter:
Successful End-of-Phase 2 meeting with the FDA for the Glucagon Emergency Administration (GEM) product candidate with a contract reached on the design of the summative human factors study, the design and objectives of the pivotal clinical trial and the product stability and analytical similarity plan for the projected 505(b)2 NDA application.
Learned that registration batches for the GEM product candidate would be received no sooner than the third calendar quarter of 2016, resulting in delayed timelines for NDA submission; engaged in discussions with device supplier regarding contract requirements, in order to provide updated program timelines.
Declared in May 2015 the initiation of a Phase 2b Study 3-250 multi-dose clinical trial of BIOD-531 ultra-rapid-acting prandial/basal insulin candidate. The study is not presently recruiting new subjects due to a request from the FDA to provide additional data concerning the investigational U-400 syringe used to deliver BIOD-531; additional syringe testing has been performed and will shortly be presented to the FDA.
Presented five abstracts at the 2015 American Diabetes Association Scientific sessions in Boston, MA from June 5-9, 2015. One oral presentation is planned for the European Association for the Study of Diabetes 51st Annual Meeting in Stockholm from September 14-18, 2015 and two abstract acceptances confirmed to date for poster presentation at the Diabetes Technology Meeting in Bethesda, MD from October 22-24, 2015.
Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency administration (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose.
Finally, Humana Inc (NYSE:HUM), ended its last trade with 0.17% gain, and closed at $186.51.
Humana Inc., has named Louis M. Fernandez, M.D., MSHI, FACOG, as its new Vice President and Chief Medical Officer of Humana South Florida.
In his new role, based in Miramar, Fla., Dr. Fernandez is responsible for clinical operations, care administration, and quality improvement for the company’s South Florida Medicare and Medicaid operations.
Dr. Fernandez joined Humana in 2012 as the Regional Medical Director for the Gulf States where he was responsible for developing and implementing the company’s clinical strategy in Louisiana and Mississippi, focusing on improving the model of care for Medicare members. In that New Orleans-based role, he also developed a new model for the utilization administration of home health services at the national level.
Humana Inc., together with its auxiliaries, operates as a health and well-being company. The company operates through three segments: Retail, Group, and Healthcare Services. The Retail segment provides Medicare and commercial fully-insured medical and specialty health insurance benefits, counting dental, vision, and other supplemental health and financial protection products directly to individuals.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
